Literature DB >> 26791406

Management of psychotropic drugs during pregnancy.

Margaret S Chisolm1, Jennifer L Payne2.   

Abstract

Psychiatric conditions (including substance misuse disorders) are serious, potentially life threatening illnesses that can be successfully treated by psychotropic drugs, even during pregnancy. Because few rigorously designed prospective studies have examined the safety of these drugs during pregnancy, the default clinical recommendation has been to discontinue them, especially during the first trimester. However, in the past decade, as more evidence has accumulated, it seems that most psychotropic drugs are relatively safe to use in pregnancy and that not using them when indicated for serious psychiatric illness poses a greater risk to both mother and child, including tragic outcomes like suicide and infanticide. This review presents an up to date and careful examination of the most rigorous scientific studies on the effects of psychotropic drugs in pregnancy. The lack of evidence in several areas means that definite conclusions cannot be made about the risks and benefits of all psychotropic drug use in pregnancy. © BMJ Publishing Group Ltd 2015.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26791406     DOI: 10.1136/bmj.h5918

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  24 in total

1.  Risk of postpartum episodes in women with bipolar disorder after lamotrigine or lithium use during pregnancy: A population-based cohort study.

Authors:  Richard Wesseloo; Xiaoqin Liu; Crystal T Clark; Steven A Kushner; Trine Munk-Olsen; Veerle Bergink
Journal:  J Affect Disord       Date:  2017-05-03       Impact factor: 4.839

Review 2.  Neuroactive Steroids and Perinatal Depression: a Review of Recent Literature.

Authors:  Katherine McEvoy; Jennifer L Payne; Lauren M Osborne
Journal:  Curr Psychiatry Rep       Date:  2018-08-09       Impact factor: 5.285

3.  Patterns of antidepressant use during pregnancy: a nationwide population-based cohort study.

Authors:  Anne Bénard-Laribière; Elodie Pambrun; Anne-Laure Sutter-Dallay; Sophie Gautier; Caroline Hurault-Delarue; Christine Damase-Michel; Isabelle Lacroix; Bernard Bégaud; Antoine Pariente
Journal:  Br J Clin Pharmacol       Date:  2018-06-03       Impact factor: 4.335

4.  Haloperidol-Associated Uterine Dystonia.

Authors:  Kathryn K Ridout; Samuel J Ridout
Journal:  Am J Psychiatry       Date:  2017-03-01       Impact factor: 18.112

5.  Recent Advances and Controversies in Peripartum Depression.

Authors:  Jennifer L Payne
Journal:  Curr Obstet Gynecol Rep       Date:  2016-07-01

Review 6.  Weighing the Risks: the Management of Bipolar Disorder During Pregnancy.

Authors:  Michael Thomson; Verinder Sharma
Journal:  Curr Psychiatry Rep       Date:  2018-03-17       Impact factor: 5.285

Review 7.  [Affective disorders during pregnancy : Therapy with antidepressants and mood stabilizers].

Authors:  N Bergemann; W E Paulus
Journal:  Nervenarzt       Date:  2016-09       Impact factor: 1.214

Review 8.  [Psychopharmacotherapy during pregnancy : Which antipsychotics, tranquilizers and hypnotics are suitable?].

Authors:  N Bergemann; W E Paulus
Journal:  Nervenarzt       Date:  2016-09       Impact factor: 1.214

9.  Patterns of prenatal antidepressant exposure and risk of preeclampsia and postpartum haemorrhage.

Authors:  Kristin Palmsten; Christina D Chambers; Alan Wells; Gretchen Bandoli
Journal:  Paediatr Perinat Epidemiol       Date:  2020-03-24       Impact factor: 3.980

Review 10.  The Safety of Second-Generation Antipsychotics During Pregnancy: A Clinically Focused Review.

Authors:  Per Damkier; Poul Videbech
Journal:  CNS Drugs       Date:  2018-04       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.